Does UnitedHealthcare Cover Prolia?

How UnitedHealthcare Classifies Prolia on Its Formulary

UnitedHealthcare places Prolia (denosumab 60 mg) on its specialty drug tier across the majority of its commercial group, individual exchange, and Medicare Advantage Part B or Part D formularies. Specialty-tier placement means the drug carries higher cost-sharing than generic or preferred brand medications, but it also means UHC acknowledges Prolia as a medically necessary treatment option for qualifying patients.

Under Medicare Advantage plans, Prolia administered in a physician's office is typically billed under Part B as a medical benefit rather than a pharmacy benefit. This distinction matters. Part B coverage often results in a 20% coinsurance after the annual deductible, which for 2025 sits at $257 [1]. For commercially insured members, the plan's specific benefit design dictates whether Prolia falls under the medical or pharmacy benefit. Members should check their Summary of Benefits or call the number on the back of their UHC card to confirm which benefit applies.

UnitedHealthcare's 2025 formulary documents list denosumab with a "PA" (prior authorization) flag and, on many plans, an "ST" (step therapy) flag [2]. These requirements are consistent across most UHC product lines, though employer-sponsored plans with custom formularies may differ.

Prior Authorization Requirements for Prolia Under UHC

Before UnitedHealthcare approves Prolia, prescribers must submit a prior authorization request documenting specific clinical criteria. The process is not optional. Without an approved PA, claims for Prolia will be denied at the pharmacy or medical claims level.

UHC's clinical coverage policy for denosumab generally requires the following: a confirmed diagnosis of osteoporosis based on a DXA scan showing a T-score of -2.5 or below at the lumbar spine, femoral neck, or total hip; OR a history of fragility fracture consistent with osteoporotic bone disease [3]. For patients with glucocorticoid-induced osteoporosis, documentation of systemic corticosteroid use equivalent to 7.5 mg or more of prednisone daily for three months or longer is typically required.

The prescriber must also document why first-line therapy is inappropriate. UHC considers oral bisphosphonates (alendronate, risedronate, ibandronate) the preferred initial treatment for most osteoporosis patients, in line with the American Association of Clinical Endocrinology (AACE) 2020 guidelines, which recommend bisphosphonates as first-line agents for patients at moderate fracture risk [4]. Prolia approval generally requires evidence of bisphosphonate failure (defined as a new fracture or continued bone density decline after 12 months of compliant therapy), intolerance (documented gastrointestinal adverse effects, esophageal disorders), or a contraindication (such as chronic kidney disease with eGFR <35 mL/min, where bisphosphonates are not recommended).

PA approvals are usually granted for 12 months, covering two injections. Renewal requests require updated clinical documentation.

Step Therapy Protocols: What UHC Expects You to Try First

Step therapy is a cost-management strategy that requires patients to try less expensive medications before the insurer will cover a higher-cost drug. For Prolia, UnitedHealthcare's step therapy protocol on most plans mandates a trial of at least one oral bisphosphonate.

This requirement is grounded in clinical evidence. The FREEDOM trial (N=7,868) demonstrated that denosumab reduced new vertebral fractures by 68% and hip fractures by 40% over 36 months compared to placebo [5]. Oral alendronate, by comparison, reduced vertebral fracture risk by roughly 44% in the Fracture Intervention Trial (FIT, N=2,027) [6]. Both drug classes are effective, but the cost differential is significant: generic alendronate runs approximately $10 to $30 per month, while Prolia's wholesale acquisition cost exceeds $1,800 per injection.

Exceptions to step therapy exist. Patients with very high fracture risk (defined by AACE as those with a T-score of -3.0 or below, or a recent vertebral or hip fracture) may qualify for step therapy override. The 2020 AACE/ACE guidelines recommend that these very-high-risk patients receive anabolic therapy (such as teriparatide or romosozumab) or denosumab as initial treatment rather than oral bisphosphonates [4]. Prescribers can cite these guidelines when requesting a step therapy exception from UHC.

Medicare Advantage vs. Commercial Plan Differences

Coverage mechanics for Prolia differ depending on whether a UHC member holds a Medicare Advantage plan or a commercial (employer-sponsored or ACA marketplace) plan. The distinction affects both out-of-pocket costs and the approval pathway.

Under UHC Medicare Advantage, Prolia administered in a physician's office is covered under the Part B medical benefit. The standard cost-share is 20% coinsurance after the Part B deductible. For a single Prolia injection with a Medicare allowable amount near $1,200, a member's coinsurance would be approximately $240 per dose, or $480 per year for two injections. Some UHC Medicare Advantage plans offer $0 copay for Part B drugs after the deductible, so actual costs vary by specific plan design [7].

For commercially insured UHC members, Prolia may be classified as either a medical benefit (if administered in-office and billed under a medical claim) or a specialty pharmacy benefit (if dispensed through UHC's specialty pharmacy network, primarily OptumRx Specialty). When processed through the specialty pharmacy, members typically face coinsurance of 20% to 40% on specialty-tier drugs, potentially reaching $300 to $700 per injection before any manufacturer copay assistance.

Dr. Andrea Singer, Director of Bone Density at MedStar Georgetown University Hospital and past president of the National Osteoporosis Foundation, has noted: "Insurance coverage variability for osteoporosis medications remains a barrier to treatment. Patients and their physicians should be proactive about understanding their specific plan benefits before initiating therapy" [8].

How to Get Prolia Approved Through UnitedHealthcare

The approval process follows a predictable sequence. Prescribers initiate a prior authorization request through UHC's online portal (UHCProvider.com), by fax, or by phone. The request must include the patient's DXA scan results, fracture history, documentation of prior bisphosphonate use (or clinical rationale for bypassing step therapy), and the prescribing physician's clinical notes supporting medical necessity.

UHC's standard turnaround for PA decisions is 72 hours for non-urgent requests and 24 hours for urgent requests under commercial plans. Medicare Advantage PA decisions follow CMS timelines: 72 hours for standard requests and 24 hours for expedited requests [9].

If the initial PA request is denied, members and prescribers have the right to appeal. The first-level appeal involves an internal review by a UHC medical director. For Medicare Advantage members, a second-level appeal goes to an Independent Review Entity (IRE) contracted by CMS. Success rates on osteoporosis medication appeals are not publicly reported by UHC, but industry data from the Kaiser Family Foundation suggests that approximately 40% to 60% of prior authorization denials are overturned on appeal when additional clinical documentation is provided [10].

A practical tip: include the patient's 10-year FRAX score (available at sheffield.ac.uk/FRAX) with the PA submission. FRAX scores quantifying major osteoporotic fracture risk above 20% or hip fracture risk above 3% strengthen the medical necessity argument, as these thresholds align with the National Osteoporosis Foundation's treatment intervention recommendations [11].

Out-of-Pocket Costs and Financial Assistance Options

The actual dollar amount a UHC member pays for Prolia depends on their specific plan's benefit design, deductible status, and whether they have access to manufacturer copay support.

For commercially insured patients, Amgen's Prolia copay card can reduce out-of-pocket costs to as little as $0 per injection, with a maximum annual benefit of $1,800. This card is not available to patients enrolled in Medicare, Medicaid, TRICARE, or other federal or state healthcare programs [12]. Medicare Advantage members who face high cost-sharing may qualify for Amgen's patient assistance program (Amgen Safety Net Foundation), which provides Prolia at no cost to patients with household incomes at or below 400% of the federal poverty level.

The AACE 2020 guidelines underscore the clinical importance of treatment continuity with denosumab: "Discontinuation of denosumab is associated with rapid bone loss and increased vertebral fracture risk. If denosumab is stopped, transition to an alternative antiresorptive agent (preferably a bisphosphonate) is recommended" [4]. This clinical reality makes consistent insurance coverage and affordability especially important for Prolia patients, as treatment gaps carry measurable skeletal consequences. In a post-hoc analysis of the FREEDOM trial extension, patients who discontinued denosumab experienced vertebral fracture rates of 7.1% within the first year of cessation, compared to 0.8% per year while on treatment [13].

Clinical Evidence Supporting Prolia Coverage

UnitedHealthcare's decision to include Prolia on its formulary reflects a body of evidence spanning multiple randomized controlled trials and real-world datasets.

The FREEDOM trial (N=7,868), published in the New England Journal of Medicine, established denosumab's efficacy over 36 months. The drug reduced the incidence of new vertebral fractures by 68% (absolute risk: 2.3% vs. 7.2% for placebo, P<0.001), hip fractures by 40%, and nonvertebral fractures by 20% [5]. The 10-year extension study demonstrated continued fracture risk reduction and progressive gains in bone mineral density, with lumbar spine BMD increasing by 21.7% from baseline over a decade of continuous treatment [14].

For glucocorticoid-induced osteoporosis, a head-to-head trial comparing denosumab to risedronate (N=795) showed that denosumab produced significantly greater BMD gains at the lumbar spine (3.8% vs. 0.8% at 12 months) in patients receiving chronic glucocorticoids [15]. This trial, published in The Lancet Diabetes & Endocrinology, directly supports the use of denosumab in a population that many UHC members fall into, particularly those with rheumatologic or pulmonary conditions requiring long-term steroid therapy.

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis in postmenopausal women recommends denosumab as a first-line option for patients at high fracture risk who cannot take oral bisphosphonates [16]. This endorsement from a major medical society provides additional clinical justification that UHC medical directors weigh during PA reviews.

Special Populations: Cancer-Related Bone Loss

Prolia carries separate FDA-approved indications for bone loss in patients receiving androgen deprivation therapy (ADT) for prostate cancer and aromatase inhibitor (AI) therapy for breast cancer. UnitedHealthcare covers Prolia for these indications, though the prior authorization criteria may reference oncology-specific clinical pathways rather than the standard osteoporosis criteria.

In the HALT-Prostate Cancer trial (N=1,468), denosumab increased lumbar spine BMD by 5.6% at 24 months in men receiving ADT, compared to a 1.0% loss in the placebo group [17]. For women on aromatase inhibitors, the ABCSG-18 trial (N=3,425) demonstrated that denosumab reduced clinical fractures by 50% compared to placebo [18].

UHC oncology clinical programs generally approve Prolia for these indications when the prescriber documents the concurrent cancer therapy and provides baseline DXA results. The PA turnaround and step therapy requirements tend to be less restrictive for cancer-related bone loss than for primary osteoporosis, because bisphosphonates are not the standard comparator in these clinical scenarios.

What Happens If UnitedHealthcare Denies Prolia Coverage

A denial does not mean the final answer is no. UHC members have structured appeal rights, and the denial letter itself must include the specific clinical rationale and instructions for filing an appeal.

For commercial plan members, the internal appeal must be filed within 180 days of the denial notice. The appeal should include any new clinical documentation not submitted with the original PA request, a letter of medical necessity from the prescribing physician, and relevant guideline citations. If the internal appeal is denied, members can request an external review by an independent third party, as required under the Affordable Care Act [19].

Medicare Advantage members follow CMS appeal timelines: 60 days to file a first-level appeal (plan reconsideration), with automatic escalation to the IRE if the plan upholds the denial. Subsequent appeal levels include an Administrative Law Judge hearing (for claims exceeding $185 in 2025) and the Medicare Appeals Council.

During the appeal process, patients who need immediate treatment can ask their prescriber about bridge therapy options. A single dose of intravenous zoledronic acid (5 mg annually) may serve as an interim antiresorptive while the Prolia appeal is pending, depending on the patient's renal function and clinical profile.